Britannin

Britannin is an NLRP3 inhibitor with an IC₅₀ of 3.630 μM, exhibiting anti-inflammatory activity. Britannin inhibits the activation and assembly of the NLRP3 inflammasome by blocking the interaction between NLRP3 and NEK7. Additionally, Britannin demonstrates antitumor activity by inhibiting the proliferation of tumor cells through blocking the interaction between HIF-1α and Myc, thereby suppressing PD-L1 expression and enhancing cytotoxic T lymphocyte activity. Britannin can also induce apoptosis and autophagy in liver cancer cells by activating ROS-regulated AMPK. Britannin holds promise for research in the fields of anti-inflammatory and antitumor therapeutics^{[1][2][3][4][5]}. In Vitro:Britannin (1, 5, 10 μM, 30 min) inhibits NLRP3-mediated pyroptosis in mouse macrophages^[4].
Britannin (1, 5, 10 μM, 30 min) inhibits activation of the NLRP3 inflammasome in an NF-κB-independent manner^[4].
In Vivo:Britannin (20 mg/kg, i.p., once daily for 3 consecutive days) ameliorates lung injury and systemic infection in Lipopolysaccharides (LPS) (HY-D1056) -induced acute lung injury mouse model in an NLRP3-dependent manner^[4].
Britannin (20 mg/kg, i.p., once every other day, for a total of 3 injections) relieves gouty arthritis in Monosodium urate (HY-B2130A) -induced gouty arthritis mouse model by inhibiting NLRP3 activation^[4].